



US006673897B1

(12) **United States Patent**
Beyaert et al.

(10) **Patent No.:** **US 6,673,897 B1**
(45) **Date of Patent:** **Jan. 6, 2004**

(54) **INHIBITORS OF NF-κB ACTIVATION**

(75) Inventors: **Rudi Beyaert**, Zingem (BE); **Karen Heyninck**, Sint-Martens-Latem (BE); **Walter Fiers**, Destelbergen (BE)

(73) Assignee: **Vlaams Interuniversitair Instituut voor Biotechnologie VZW**, Zwijnaarde (BE)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 90 days.

(21) Appl. No.: **09/702,953**

(22) Filed: **Oct. 31, 2000**

Related U.S. Application Data

(63) Continuation of application No. PCT/BE99/00055, filed on May 5, 1999.

(30) **Foreign Application Priority Data**

May 6, 1998 (EP) 98201472

(51) **Int. Cl.**⁷ **C07K 1/00**; C07K 14/00; A61K 38/00

(52) **U.S. Cl.** **530/350**; 514/2; 930/10

(58) **Field of Search** 530/350; 514/2; 930/10

(56) **References Cited**

FOREIGN PATENT DOCUMENTS

WO WO 97/37016 10/1997

OTHER PUBLICATIONS

Yamamoto et al. Therapeutic potential of inhibition of the NF-κappaB pathway in the treatment of inflammation and cancer. Jan. 2001, J. Clin. Invest. vol. 107, No. 2, pp. 135-142.*

Ghosh et al. Missing Pieces in the NF-κappaB Puzzle. Apr. 2002, Cell, vol. 109, pp. S81-S96.*

Baldwin, A.S. The transcription factor NF-κappaB and Human disease. Jan. 2001, J. Clin. Invest. vol. 107, No. 1, pp. 3-6.*

Ngo et al. Computational Complexity, Protein Structure Prediction and the Levinthal Paradox., 1994, The Protein Folding Problem and Tertiary Structure, Marz et al. ed., pp. 14-16.*

Zhang et al. Environment-dependent residue contact energies for proteins. Mar. 2000, Proc. Natl. Acad. Sci. vol. 97, No. 6, pp. 2550-2555.*

Fukushi et al. (Nov. 1, 1996) Acc. No. Q15025, SPTREMBL_17 database, GenCore Version 4.5, Accessed May 8, 2002.*

Gupta et al. (Mar. 1, 2001) Acc. No. Q9H1J3, SPTREMBL_17, GenCore Version 4.5, Accessed May 8, 2002.*

De Valck et al., "A20, an inhibitor of cell death, self-associates by its zinc finger domain", *FEBS Letters*, 384, pp. 61-64, 1996.

Fukushi M., "Homo sapiens mRNA for HIV-1, Nef-associated factor 1 beta (Naf1 beta)" EMHUM Database Entry HSA011896, Accession No. AJ011896, Oct. 14, 1998, XP002124741.

Fukushi M. et al., "NAF1 alpha protein (KIAA0113 protein)", TREMB1 Database Entry Q15025, Accession No. Q15025, Nov. 1, 1996, XP02124740.

Hendrich BD et al., "An X-linked homologue of the autosomal imprinted gene NF127 escapes X chromosome inactivation.", EMHUM Database Entry HS4131510; Accession No. U41315, May 19, 1996, XP002125387.

Heyninck et al., "The Zinc Finger Protein A20 Inhibits TNF-induced NF-κB-dependent Gene Expression by Interfering with an RIP- or TRAF2-mediated Transactivation Signal and Directly Binds to a Novel NF-κB-inhibiting Protein ABIN", *The Journal of Cell Biology*, vol. 145, pp. 1471-1482, 1999.

Miyajima N. et al., "Human mRNA for KIAA 0133 gene, partial coding sequence" EMHUM Database Entry HSORFA2, Accession No. D30755, May 21, 1994, XP002124739.

Nomura et al., 'mRNA for ORF, partial CDS (fragment)', TRHUM Database entry Q15025; Nov. 1, 1996, Accession No. Q15025, XP002080989.

Song et al., "The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-κB activation", *Proc. Natl. Acad. Sci. USA*, 93, pp. 6721-6725, 1996.

Yen Rwc et al., 'DNA-methyltransferase.', SWISSPROT Database entry MTDM_HUMAN; May 1, 1992; Accession No. P26358, XP002080990.

PCT International Search Report, PCT/BE99/00055, dated Dec. 31, 1999, 9 pages.

PCT International Preliminary Examination Report, PCT/BE99/00055, dated Aug. 10, 2000.

* cited by examiner

Primary Examiner—Christopher S. F. Low

Assistant Examiner—Holly Schnizer

(74) *Attorney, Agent, or Firm*—TraskBritt

(57) **ABSTRACT**

The present invention relates to novel inhibitors of the Nuclear factor kappa B (NF-κB) activating pathway useful in the treatment of NF-κB related diseases and/or in the improvement of anti-tumor treatments. These inhibitors interfere early in the TRAF induced signaling pathway and are therefore more specific than IκB.

6 Claims, 10 Drawing Sheets